Other haematological malignancies expressing high levels of both Bcl-2 and Mcl-1, such as multiple myeloma [71], may also benefit from the venetoclax and ATO combination, which needs to be validated in future research. The gene discussed is BCL2; the disease is plasma cell myeloma.